Modern approaches to the rational choice of antibiotic for treatment of community-acquired pneumonia in various categories of patients

Community-acquired pneumonia (CAP) is the leader among respiratory tract infections. The severity of CAP varies from mild forms (outpatient treatment) to severe, requiring hospitalization. A signifi cant number of negative clinical outcomes, including lethal, actualize regular analysis of patient’s management strategies with a focus on a rational antibiotic therapy. The purpose of the review is to evaluate a rational approach to the choice of an empirical drug for antibiotic therapy of CAP in diff erent patient populations. This review includes an analysis of modern clinical guidelines for CAP antibiotic therapy in pediatric patients and adults, considering current data on the resistance of the main pathogens and the results of clinical effi cacy trials involving antimicrobials listed in the given guidelines. Analysis of the prevalence of causative agents of CAP reveals leading positions of Streptococcus pneumoniae and atypical microfl ora with a tendency to increase of the role of potentially resistant microorganisms — Staphylococcus aureus and Gram-negatives (Pseudomonas aeruginosa, Haemophilus infl uenzae, family of Enterobacteriaceae). The schemes of CAP empiric antibiotic therapy in adults and children according to the clinical guidelines in Europe, USA, and Russia include β-lactams, macrolides, respiratory fl uoroquinolones and doxycycline. In Russian Federation, a suffi ciently high level of sensitivity of major CAP pathogens is detected for β-lactams (inhibitorprotected aminopenicillins, third-generation cephalosporins), respiratory fl uoroquinolones and macrolides (azithromycin, clarithromycin). Analysis of clinical effi cacy trials of empiric antibiotic therapy revealed benefi ts of aminopenicillins in treatment of outpatients, except in cases caused by atypical microfl ora macrolides are the drug of choice. The combination of β-lactam antibiotic plus macrolide is indicated for patients with increased CAP severity rates and risks of atypical microfl ora. Inhibitor-protected β-lactams, cephalosporins II and III generations, and respiratory fl uoroquinolones are essential to treat severe CAP.

1. Postma DF, van Werkhoven CH, VanElden LJR, et al. Antibiotic treatment strategies for community acquired pneumonia in adults. N Engl J Med. 2015;372:1312—1323. DOI: 10.1056/NEJMoa1406330.

2. https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.

3. Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-Lactam-macrolide combination treatment in moderately severe communityacquired pneumonia: a randomized non-inferiority trial. JAMAInternMed. 2014;174(12):1894—1901. DOI: 10.1001/jamainternmed.2014.4887.

4. Bilichenko TN, Chuchalin AG. Morbidity and mortality of the Russian population from acute respiratory viral infections, pneumonia and vaccination. Terapevticheskii arkhiv. 2018;(1):22—26 (In Russ). DOI: 10.17116/terarkh201890122-26.

5. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. CritCareMed. 2014 Feb;42(2):420—32. DOI: 10.1097/CCM.0b013e3182a66b9b.

6. Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18(4):761—76, vii. DOI: 10.1016/j.idc.2004.08.003.

7. Eljaaly K, Alshehri S, Aljabri A, etal. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with communityacquired pneumonia: a systematic review and meta-analysis. BMC InfectDis. 2017;17(1):385. DOI:10.1186/s12879-017-2495-5.

8. Forest WA, Timothy LW, Paula P, Julio AR. Mortality diff erences among hospitalized patients with community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respiratory Medicine. 2013;107(7):1101—1111. DOI: 10.1016/j.rmed.2013.04.003.

9. Okumura J, Shindo Y, Takahashi K, et al. Central Japan Lung Study Group Mortality in patients with community-onset pneumonia at low risk of drugresistant pathogens: Impact of β-lactam plus macrolide combination therapy. Respirology. 2018;23(5):526—534. DOI: 10.1111/resp.13232.

10. Lopardo GD, Fridman D, Raimondo E. Incidence rate of communityacquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America. BMJ Open. 2018;8:e019439. DOI: 10.1136/bmjopen-2017-019439.

11. Ambroggio L, Test M, Metlay JP, et al. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia. Pediatr Pulmonol. 2015;51(5):541—8. DOI: 10.1002/ppul.23312.

12. Rodrigues CMC, Groves H. Community-Acquired Pneumonia in Children: the Challenges of Microbiological Diagnosis. J Clin Microbiol. 2018;56(3):e01318-17. DOI:10.1128/JCM.01318-17

13. Tansarli GS, Mylonakis E. Systematic Review and Meta-analysis of the Effi cacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. Antimicrobial Agents and Chemotherapy. 2018;62 (9): e00635-18. DOI: 10.1128/AAC.00635-18.

14. Rodrigues CMC. Challenges of Empirical Antibiotic Th erapy for Community-Acquired Pneumonia in Children. Curr Th er Res Clin Exp. 2017;16(84):e7-e11. DOI: 10.1016/j.curtheres.2017.01.002.

15. File TM, Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifl oxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blindstudy. Journal of Antimicrobial Chemotherapy. 2007;60(1):112—120. DOI: 10.1093/jac/dkm119.

16. Cillóniz C, Rodríguez-Hurtado D, Torres A. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. Med Sci (Basel). 2018;6(2):35. DOI:10.3390/medsci6020035.

17. Dunbar LM, Khashab MM, Kahn JB, et al. Effi cacy of 750-mg, 5-day levofl oxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin. 2004;20(4): 555—563. DOI: 10.1185/030079904125003304.

18. Jain S, Self WH, Wunderink RG et al. CDC EPIC Study Team. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015;373(5):415—27. DOI: 10.1056/NEJMoa1500245.

19. Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Current Medical Research and Opinion. 2004;20(5):739—747. DOI:10.1185/030079904125003610.

20. Ewig S, Birkner N, Strauss R, et al. New perspectives on communityacquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Th orax. 2009;64(12):1062—9. DOI: 10.1136/thx.2008.109785.

21. Léophonte P, Choutet P, Gaillat J, et al. Effi cacy of a ten day course of ceft riaxone compared to a shortened fi ve day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Medecine et Maladies Infectieuses. 2002;32(7):369—381.

22. Vila-Corcoles Al, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F; EPIVAC Study Group. Epidemiology of communityacquired pneumonia in older adults: a population-based study. RespirMed. 2009;103(2):309—16. DOI: 10.1016/j.rmed.2008.08.006.

23. Uranga A, España PP, Bilbao A, et al. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med. 2016;176(9):1257—65. DOI: 10.1001/jamainternmed.2016.3633.

24. Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Vaccine. 2015;33(28):3193—9. DOI: 10.1016/j.vaccine.2015.05.001.

25. Nascimento-Carvalho AC, Nascimento-Carvalho CM. Clinical management of community-acquired pneumonia in young children. Expert OpinPharmacother. 2019;20(4):435—442. DOI: 10.1080/14656566.2018.

26. Wang J, Li F, Tian Z. Role of microbiota on lung homeostasis and diseases. Sci. ChinaLifeSci. 2017;60:1407. DOI: 10.1007/s11427-017-9151-1.

27. Nascimento-Carvalho CM, Andrade DC, Vilas-Boas AL. An update on antimicrobial options for childhood community-acquired pneumonia: a critical appraisal of available evidence. ExpertOpinPharmacother. 2016;17(1):53—78. DOI: 10.1517/14656566.2016.1109633.

28. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. European Respiratory Journal. 2002;20: 20s-27s; DOI: 10.1183/09031936.02.00702002

29. Quaak CH, Cové E, Driessen GJ, Tramper-Stranders GA. Trends in paediatric inpatient antibiotic therapy in a secondary care setting. Eur J Pediatr. 2018;177(8):1271—1278. DOI: 10.1007/s00431-018-3185-z.

30. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. Th e aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33(7):1065—79. DOI: 10.1007/s10096-014-2067-1.

31. Capelastegui A, España PP, Bilbao A, et al. Etiology of communityacquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis. 2012;12:134. DOI: 10.1186/1471-2334-12-134.

32. Wuerth BA, Bonnewell JP, Wiemken TL, et al. Trends in Pneumonia Mortality Rates and Hospitalizations by Organism, United States, 2002—2011. Emerging Infectious Diseases. 2016;22(9):1624—1627. DOI:10.3201/eid2209.150680.

33. Boyles TH, Brink A, Calligaro GL, et al. South African guideline for the management of community-acquired pneumonia in adults. J Thorac Dis. 2017;9(6):1469—1502. DOI: 10.21037/jtd.2017.05.31.

34. Peto L, Nadjm B, Horby P, et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2014;108(6):326—37. DOI: 10.1093/trstmh/tru058.

35. Arnold FW, La Joie AS, Brock GN, et al. Community-Acquired Pneumonia Organization (CAPO) Investigators. Improving out-comes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009;169:1515—24. DOI: 10.1001/archinternmed.2009.265.

36. Lim WS, Baudouin SV, George RC et al. Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009; 64 Suppl 3:iii1-55. DOI: 10.1136/thx.2009.121434.

37. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America., American Th oracic Society. Infectious Diseases Society of America/American Th oracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(2):S27—72. DOI: 10.1086/511159.

38. Woodhead M. New guidelines for the management of adult lower respiratory tract infections. European Respiratory Journal. 2011;38:1250—1251. DOI: 10.1183/09031936.00105211.

39. Chuchalin AG, Sinopal’nikov AI, Kozlov RS, Tyurin IE, Rachina SA. Vnebol’nichnaya pnevmoniya u vzroslykh: prakticheskie rekomendatsii po diagnostike, lecheniyu i profi laktike (Posobie dlya vrachei). Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2010;12(3):186—225. (In Russ).

40. Chuchalin AG, Sinopal’nikov AI, Kozlov RS, Avdeev SN, Tyurin IE, Rudnov VA, Rachina SA, Fesenko OV. Rossiiskoe respiratornoe obshchestvo (RRO) Mezhregional’naya assotsiatsiya po klinicheskoi mikrobiologii i antimikrobnoi khimioterapii (MAKMAKh) Klinicheskie rekomendatsii po diagnostike, lecheniyu i profi laktike tyazheloi vnebol’nichnoi pnevmonii u vzroslykh. Pul’monologiya. 2014;4:13—48. (In Russ). DOI 10.18093/0869-0189-2014-0-4-13-48.

41. http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskierekomendatsii/

42. Paediatric Formulary Committee BNF for children 2016—2017. Vol. 12 London: BMJ Group, Pharmaceutical Press and RCPCH Publications; 2016.

43. Sharland M, Butler K, Cant A, et al. OSH manual of childhood infections. The blue book. Oxford: Oxford University Press; 2016.

44. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, Thomson A. British Th oracic Society Standards of Care Committee. Th orax. 2011;66(2):ii1-23. DOI: 10.1136/thoraxjnl-2011-200598.

45. Le Saux N, Robinson J. Pneumonia in healthy Canadian children and youth: Practice points for management. Paediatr Child Health. 2011;16(7):417—24.

46. Bradley JS, Byington CL, Shah SS et al. Th e Management of Community-Acquired Pneumonia in Infants and Children Older Th an 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clinical Infectious Diseases. 2011; 53 (7): e25—e76. DOI: 10.1093/cid/cir531.

47. Vnebol’nichnaya pnevmoniya u detei. Klinicheskie rekomendatsii. — Moskva: Original-maket, 2015. (in Russ).

48. Amalakuhan B, Echevarria KL, Restrepo MI. Managing community acquired pneumonia in the elderly — the next generation of pharmacotherapy on the horizon. Expert Opin Pharmacother. 2017;18(11):1039—1048. DOI: 10.1080/14656566.2017.1340937.

49. Luan Y, Sun Y, Duan S, Zhao P, Bao Z. Pathogenic bacterial profi le and drug resistance analysis of community-acquired pneumonia in older outpatients with fever. J Int Med Res. 2018;46(11):4596—4604 DOI: 10.1177/0300060518786915.

50. Ma Jinghua, Liu Gaizhuang, Chai Qiaoli. Pathogens and antibiotic resistance of children with community-acquired pneumonia. Biomedical Research 2017;28(20):8839—8843.

51. Adhikari R, Shrestha S. Prevalence and antibiotic sensitivity profiles of bacteria causing community acquired pneumonia. International Journal of Infectious Diseases. 2016;45(1):81. DOI: 10.1016/j.ijid.2016.02.223.

52. Rachina SA, Kozlov RS, Dekhnich NN, et al. Antibakterial’naya terapiya tyazheloi vnebol’nichnoi pnevmonii u vzroslykh: obzor rekomendatsii i klinicheskie primery. Arkhiv» vnutrennei meditsiny. 2015;3:63—74 (In Russ). DOI: 10.20514 / 2226-6704-2015-0-3-63-74.

53. Sinopal’nikov AI. Levofl oksatsin: rol’ i mesto v lechenii infektsii nizhnikh dykhatel’nykh putei. Klinicheskaya meditsina. 2016;11:851—860. (In Russ). DOI: 10.18821/0023-2149-2016-94-11-851-860.

54. Maianskii NA, Aliab’eva NM, Ponomarenko OA. et al. Dinamika rasprostranennosti serotipov i antibiotikorezistentnosti nosoglotochnykh pnevmokokkov, vydelennykh u detei v 2010—2016 gg.: rezul’taty retrospektivnogo kogortnogo issledovaniia. Vopr. sovrem. pediatrii. 2017;16(5):413—23. (In Russ). DOI: 10.15690/vsp.v16i5.1806.

55. http://grls.rosminzdrav.ru/grls.aspx.

56. Gidal A, Barnett S. Risk Factors Associated With Multidrug-Resistant Pneumonia in Nonhospitalized Patients. Fed Pract. 2018;35(1):16—18.

57. Aspa J, Rajas O, Rodríguez de Castro F et al. Infectious Diseases in Clinical Practice. 2008;16(6):368—375. DOI: 10.1097/IPC.0b013e31817eec69.

58. Postma DF, van Werkhoven CH, VanElden LJR, et al. Antibiotic treatment strategies for community acquired pneumonia in adults. N Engl J Med. 2015;372:1312—1323. DOI: 10.1056/NEJMoa1406330.

59. Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-Lactam-macrolide combination treatment in moderately severe communityacquired pneumonia: a randomized non-inferiority trial. JAMAInternMed. 2014;174(12):1894—1901. DOI: 10.1001/jamainternmed.2014.4887.

60. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. CritCareMed. 2014 Feb;42(2):420—32. DOI: 10.1097/CCM.0b013e3182a66b9b.

61. Eljaaly K, Alshehri S, Aljabri A, etal. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with communityacquired pneumonia: a systematic review and meta-analysis. BMC InfectDis. 2017;17(1):385. DOI:10.1186/s12879-017-2495-5.

62. Okumura J, Shindo Y, Takahashi K, et al. Central Japan Lung Study Group Mortality in patients with community-onset pneumonia at low risk of drugresistant pathogens: Impact of β-lactam plus macrolide combination therapy. Respirology. 2018;23(5):526—534. DOI: 10.1111/resp.13232.

63. Ambroggio L, Test M, Metlay JP, et al. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia. Pediatr Pulmonol. 2015;51(5):541—8. DOI: 10.1002/ppul.23312.

64. Tansarli GS, Mylonakis E. Systematic Review and Meta-analysis of the Effi cacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. Antimicrobial Agents and Chemotherapy. 2018;62 (9): e00635-18. DOI: 10.1128/AAC.00635-18.

65. File TM, Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifl oxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blindstudy. Journal of Antimicrobial Chemotherapy. 2007;60(1):112—120. DOI: 10.1093/jac/dkm119.

66. Dunbar LM, Khashab MM, Kahn JB, et al. Effi cacy of 750-mg, 5-day levofl oxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin. 2004;20(4): 555—563. DOI: 10.1185/030079904125003304.

67. Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Current Medical Research and Opinion. 2004;20(5):739—747. DOI:10.1185/030079904125003610.

68. Léophonte P, Choutet P, Gaillat J, et al. Effi cacy of a ten day course of ceft riaxone compared to a shortened fi ve day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Medecine et Maladies Infectieuses. 2002;32(7):369—381.

69. Uranga A, España PP, Bilbao A, et al. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med. 2016;176(9):1257—65. DOI: 10.1001/jamainternmed.2016.3633.

70. Nascimento-Carvalho AC, Nascimento-Carvalho CM. Clinical management of community-acquired pneumonia in young children. Expert OpinPharmacother. 2019;20(4):435—442. DOI: 10.1080/14656566.2018.

71. Nascimento-Carvalho CM, Andrade DC, Vilas-Boas AL. An update on antimicrobial options for childhood community-acquired pneumonia: a critical appraisal of available evidence. ExpertOpinPharmacother. 2016;17(1):53—78. DOI: 10.1517/14656566.2016.1109633.

72. Quaak CH, Cové E, Driessen GJ, Tramper-Stranders GA. Trends in paediatric inpatient antibiotic therapy in a secondary care setting. Eur J Pediatr. 2018;177(8):1271—1278. DOI: 10.1007/s00431-018-3185-z.